32 results
6-K
EX-99.2
CNTG
Centogene NV
28 Nov 23
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
6:30am
required for NV and its Affiliates to provide the NV Services. NV and its Affiliates will abide by all site health, safety and other procedures … or representative and is in NV’s or any of its Affiliates’ possession concerning the NV Services (including material information relating to
the safety
6-K
EX-99.3
CNTG
Centogene NV
28 Nov 23
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
6:30am
by applying Commercially Reasonable Efforts to provide levels of accuracy, quality, safety, completeness, timeliness and care consistent … , removal, market withdrawal or replacement, corrective action, or any other safety notice alleging a lack of safety or efficacy or regulatory compliance
6-K
EX-99.2
CNTG
Centogene NV
27 Oct 23
Variation Agreement to Joint Venture Agreement
7:28am
or supplemented from time to time.
“Safety Notices” has the meaning set forth in Section 4(y)(ii).
“Sanctions” means economic or financial sanctions or trade … notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory compliance of the Borrower’s products
6-K
EX-99.3
CNTG
Centogene NV
27 Jun 23
Current report (foreign)
9:36am
GmbH, Careventures Fund II S.C.Sp, and TVM Life Science Innovation I, L.P., as the same may be amended or supplemented from time to time.
“Safety … withdrawals or replacements, warnings, “dear doctor” letters, investigator notices, safety alerts or other notice of action relating to an alleged lack
6-K
EX-99.1
CNTG
Centogene NV
16 May 23
CENTOGENE Reports Full Year 2022 Financial Results
5:43pm
., is currently evaluating the efficacy and safety of BIIB122 (DNL151), a small molecule LRRK2 inhibitor
Extended and expanded, with support from Alector, Inc
6-K
EX-99.1
ua0a1z
3 Oct 22
Current report (foreign)
8:00am
6-K
EX-99.1
bzhjsy4t
13 Jun 22
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease
6:30am
6-K
EX-99.4
f4cmshm ostb59g
1 Feb 22
CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan
9:30am
6-K
EX-99.1
wp4k1k24
20 Oct 20
Current report (foreign)
8:15am
6-K
EX-99.1
e4oy9zm8 h9
15 Oct 20
Collaboration Between CENTOGENE and U-Diagnostics Increases COVID-19 Testing Capacities in the Netherlands
6:02am
F-1
EX-1.1
ntghhi v38s391
7 Jul 20
Registration statement (foreign)
5:29pm
20-F
d3413u1joves7
23 Apr 20
Annual report (foreign)
9:28am